Actinium Pharmaceuticals, Inc ARS, filed Oct 16, 2026

Actinium Pharmaceuticals, Inc. (ATNM)

Actinium Pharmaceuticals' 2025 Annual Report describes it as a clinical-stage biopharmaceutical company developing targeted radiotherapies for solid tumors and hematologic malignancies, highlighting lead candidate ATNM-400's pre-clinical activity across mCRPC, NSCLC, and breast cancer. AI summary